Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

862.30INR
18 Jan 2019
Change (% chg)

Rs-6.45 (-0.74%)
Prev Close
Rs868.75
Open
Rs861.10
Day's High
Rs867.35
Day's Low
Rs851.85
Volume
1,824,696
Avg. Vol
2,082,709
52-wk High
Rs986.10
52-wk Low
Rs723.65

Latest Key Developments (Source: Significant Developments)

Lupin's Orphan Drug Namuscla® Receives European Commission Approval
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Lupin Ltd ::LUPIN LIMITED: ORPHAN DRUG NAMUSCLA® RECEIVES EUROPEAN COMMISSION APPROVAL FOR THE TREATMENT OF MYOTONIA IN NON-DYSTROPHIC MYOTONIC DISORDERS.PARTNERING DISCUSSIONS ONGOING FOR COMMERCIALIZATION OF NAMUSCLA® IN EUROPEAN TERRITORIES OUTSIDE GERMANY AND UK.LUPIN IS PREPARING FOR LAUNCH OF NAMUSCLA®, WHICH WILL OCCUR IN INITIAL MARKETS OF GERMANY AND UK IN Q1 2019.  Full Article

Lupin Gets FDA Approval For Clobazam Oral Suspension, 2.5 Mg/Ml
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES FDA APPROVAL FOR CLOBAZAM ORAL SUSPENSION, 2.5 MG/ML..  Full Article

India's Lupin Receives Tentative U.S FDA Approval For Dimethyl Fumarate Delayed Release Capsules
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES TENTATIVE US FDA APPROVAL FOR DIMETHYL FUMARATE DELAYED RELEASE CAPSULES, 120 MG AND 240 MG..  Full Article

Lupin Says EU General Court Upholds European Commission’S Decision In Perindopril Litigation
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Lupin Ltd ::SAYS EU GENERAL COURT UPHOLDS EUROPEAN COMMISSION’S DECISION IN PERINDOPRIL LITIGATION.GENERAL COURT UPHELD EC’S DECISION HOLDING LUPIN LIABLE TO PAY FINE OF 40 MILLION EUROS.  Full Article

Lupin Says USFDA Inspection Of Mandideep Facility Closes With 22 Observations
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - Lupin Ltd ::SAYS US FDA COMPLETES INSPECTION OF LUPIN'S MANDIDEEP LOCATION.SAYS INSPECTION AT UNIT-2, THE CARDIOVASCULAR "PRIL" API FACILITIES CLOSED WITH 4 OBSERVATIONS.UNIT-I INSPECTION CLOSED WITH 10 OBSERVATIONS FOR CEPHALOSPORIN API FACILITIES,8 OBSERVATIONS FOR CEPHALOSPORIN SOLID ORAL DOSAGE FORM FACILITY.THERE ARE NO NEW DMF AND ANDA APPLICATIONS PENDING FOR REVIEW OR APPROVAL FROM LUPIN'S MANDIDEEP FACILITIES.OBSERVATIONS ARE LARGELY PROCEDURAL IN NATURE WITH SOME GAPS IDENTIFIED IN THE ASEPTIC PROCESSING AREAS OF THE CEPHA LOSPORIN API BLOCK.  Full Article

Lupin Launches Generic Nystatin And Triamcinolone Acetonide Cream USP
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Lupin Ltd ::SAYS CO LAUNCHES GENERIC NYSTATIN AND TRIAMCINOLONE ACETONIDE CREAM USP 100,000 UNITS/GM; 0.1%.  Full Article

Lupin Says CFO Ramesh Swaminathan Resigns
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Lupin Ltd ::RAMESH SWAMINATHAN, CHIEF FINANCIAL OFFICER, RESIGNS.  Full Article

Lupin Gets FDA Approval For KCL For Oral Solution 20 Meq
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Lupin Ltd ::SAYS CO GETS FDA APPROVAL FOR KCL FOR ORAL SOLUTION 20 MEQ.  Full Article

Lupin Launches Generic Tetrabenazine Tablets
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Lupin Ltd ::LAUNCHES GENERIC TETRABENAZINE TABLETS.LUPIN LTD <<>> SAYS DRUGS INDICATED FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE..  Full Article

India's Lupin Launches Generic Atovaquone Oral Suspension USP In U.S
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lupin Ltd ::LAUNCHES GENERIC ATOVAQUONE ORAL SUSPENSION USP IN THE U.S.  Full Article

UPDATE 1-India's Lupin Q2 profit dives as U.S. sales, higher expenses weigh

Oct 31 Lupin Ltd, India's second-largest drugmaker by revenue, posted a lower-than-expected second-quarter profit on Wednesday, as sales in the United States - a key market - dropped and overall manufacturing costs rose.